2seventy bio Aktie News

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT) announced today that members of the management team will present at the following upcoming investor conferences: TD Cowen 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA in a virtual fireside chat on Tuesday, May 28, 2024 at 8:30 a.m. ET Goldman Sachs 45th Annual Global Healthcare Conference in Miami Beach, FL, ...

2seventy bio, Inc. (NASDAQ:TSVT ) Q1 2024 Earnings Conference Call May 8, 2024 8:00 AM ET Company Participants Jenn Snyder - Senior Vice President, Corporate Affairs Chip Baird - Chief Executive Officer Vicki Eatwell - Chief Financial Officer Anna Truppel-Hartmann - Chief Medical Officer Conference Call Participants Rabib Chaudhury - Leerink Partners Matt Leskowitz - Goldman Sachs Kelsey Goodwi...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), today reported financial results and recent highlights for the first quarter ended March 31, 2024. “In the first quarter of 2024, we have successfully completed a strategic re-alignment to focus exclusively on Abecma, seeking to impact many more patients in earlier lines and return to commercial growth. In turn, we are focuse...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT) will announce its first quarter 2024 financial results on Wednesday, May 8, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Participants can access the conference call live via webcast which will be available on the Investors and Media page of the company's website at https://ir.2seventybio.com. Participants ...

2seventy bio is focusing on ABECMA, their CAR-T cell therapy for multiple myeloma, and expects label expansion approval. ABECMA has shown positive real-world evidence and has the potential for significant market growth. The company's financial position is strong, with a cash runway past 2027, and they anticipate a return to growth if the label expansion is approved.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), announced today that Eli Casdin, Chief Investment Officer, and Founder of Casdin Capital, and Charles Newton, Chief Financial Officer, Lyell Immunopharma, have been appointed as new independent members of the Company's Board of Directors (the “Board”), effective immediately. Casdin Capital owns approximately 2.3% of 2seventy ...

2Seventy Bio, Inc. (NASDAQ:TSVT ) Q4 2023 Earnings Conference Call March 5, 2024 8:00 AM ET Company Participants Elizabeth Hickin - Head, IR Chip Baird - Incoming CEO Vicki Eatwell - Incoming CFO Anna Truppel-Hartmann - SVP, Clinical Development Conference Call Participants Daina Graybosch - Leerink Partners Tommie Reerink - Goldman Sachs & Co. Kelsey Goodwin - Guggenheim Securities Samantha Se...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #TSVT--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today reported financial results and recent highlights for the fourth quarter and full year ended December 31, 2023. “In the past weeks and months, 2seventy has made significant changes to our business and cost structure designed to optimize our ability to unlock value f...